ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals

ARC 靶向放射性药物先进制造研究中心

• 批准号: IH220100017
• 负责人: Prof Kristofer Thurecht
• 金额: $ 332.45万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Industrial Transformation Research Hubs
• 财政年份: 2023
• 资助国家: 澳大利亚
• 起止时间: 2023-09-08 至 2028-09-07
• 项目状态: 未结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/IH220100017
• 关键词: ARC; Research; Hub; Advanced; Manufacture

Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry. The program establishes a dedicated manufacturing pipeline, future-proofing production and securing supply chain of next generation medical technologies.

放射性药物正在成为应对复杂健康挑战的下一代医疗技术，其生产为澳大利亚带来了巨大的经济效益。ARC靶向放射性药物先进制造研究中心（AMTAR）旨在建立一个结合生物技术和制药科学创新的新医疗技术制造平台。该计划解决了生物制品作为分子放射性药物的翻译，生物制造，放射生物学和放射化学能力建设的行业主导的挑战。该计划建立了专门的制造管道，面向未来的生产和下一代医疗技术的安全供应链。